{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:29:26Z","timestamp":1763051366646,"version":"3.45.0"},"reference-count":66,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.soc.2025.02.001","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:19:42Z","timestamp":1744478382000},"page":"103-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Surgical Resection for Borderline and Locally Advanced Pancreatic Adenocarcinoma"],"prefix":"10.1016","volume":"35","author":[{"given":"Omar","family":"Haque","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne G.","family":"Warner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib1","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"10.1016\/j.soc.2025.02.001_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.4708","article-title":"Estimated projection of US cancer incidence and death to 2040","volume":"4","author":"Rahib","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"Suppl 9","key":"10.1016\/j.soc.2025.02.001_bib3","first-page":"141","article-title":"Epidemiology and risk factors of pancreatic cancer","volume":"89","author":"Mario","year":"2018","journal-title":"Acta Bio Medica Atenei Parm"},{"issue":"10242","key":"10.1016\/j.soc.2025.02.001_bib4","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(20)30974-0","article-title":"Pancreatic cancer","volume":"395","author":"Mizrahi","year":"2020","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib5","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s41571-023-00746-1","article-title":"Neoadjuvant therapy for pancreatic cancer","volume":"20","author":"Springfeld","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib6","first-page":"5","article-title":"Cancer statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 5","key":"10.1016\/j.soc.2025.02.001_bib7","doi-asserted-by":"crossref","first-page":"v56","DOI":"10.1093\/annonc\/mdv295","article-title":"Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Ducreux","year":"2015","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.02.001_bib8","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.3390\/curroncol31040167","article-title":"Multimodal approaches to patient selection for pancreas cancer surgery","volume":"31","author":"Muaddi","year":"2024","journal-title":"Curr Oncol Tor Ont"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1091-255X(01)80010-X","article-title":"Preoperative chemoradiation for marginally resectable adenocarcinoma of the pancreas","volume":"5","author":"Mehta","year":"2001","journal-title":"J Gastrointest Surg Off J Soc Surg Aliment Tract"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"4","key":"10.1016\/j.soc.2025.02.001_bib11","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib12","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.21037\/jgo-21-119","article-title":"Selecting surgical candidates with locally advanced pancreatic cancer: a review for modern pancreatology","volume":"12","author":"Wu","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib13","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.21037\/jgo-2020-slapc-04","article-title":"Resectable, borderline, and locally advanced pancreatic cancer\u2014\u201cthe good, the bad, and the ugly\u201d candidates for surgery?","volume":"12","author":"Bratlie","year":"2021","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"10.1016\/j.soc.2025.02.001_bib14","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1200\/JOP.2016.016162","article-title":"Multimodality therapy in patients with borderline resectable or locally advanced pancreatic cancer: importance of locoregional therapies for a systemic disease","volume":"12","author":"Tsai","year":"2016","journal-title":"J Oncol Pract"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib15","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.surg.2017.09.012","article-title":"Locally advanced pancreas cancer: staging and goals of therapy","volume":"163","author":"Chatzizacharias","year":"2018","journal-title":"Surgery"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib16","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1245\/s10434-021-10663-1","article-title":"Anatomic criteria determine resectability in locally advanced pancreatic cancer","volume":"29","author":"Gemenetzis","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib17","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jamcollsurg.2020.05.005","article-title":"En bloc celiac axis resection for pancreatic cancer: classification of anatomical variants based on tumor extent","volume":"231","author":"Truty","year":"2020","journal-title":"J Am Coll Surg"},{"issue":"31","key":"10.1016\/j.soc.2025.02.001_bib18","doi-asserted-by":"crossref","first-page":"10740","DOI":"10.3748\/wjg.v20.i31.10740","article-title":"Borderline resectable pancreatic cancer: definitions and management","volume":"20","author":"Lopez","year":"2014","journal-title":"World J Gastroenterol WJG"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib19","first-page":"375","article-title":"Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma","volume":"70","author":"Grossberg","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/SLA.0000000000005925","article-title":"Neoadjuvant chemotherapy versus upfront surgery for resectable pancreatic adenocarcinoma: an updated nationwide study","volume":"279","author":"Sugawara","year":"2024","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib21","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S2468-1253(22)00348-X","article-title":"Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable pancreatic cancer (ESPAC5): a four-arm, multicentre, randomised, phase 2 trial","volume":"8","author":"Ghaneh","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.soc.2025.02.001_bib22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1093\/jnci\/djz073","article-title":"Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review and patient-level meta-analysis","volume":"111","author":"Janssen","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"17","key":"10.1016\/j.soc.2025.02.001_bib23","doi-asserted-by":"crossref","first-page":"4326","DOI":"10.3390\/cancers13174326","article-title":"Efficacy and safety of neoadjuvant gemcitabine plus nab-paclitaxel in borderline resectable and locally advanced pancreatic cancer-a systematic review and meta-analysis","volume":"13","author":"Damm","year":"2021","journal-title":"Cancers"},{"issue":"Suppl 3","key":"10.1016\/j.soc.2025.02.001_bib24","doi-asserted-by":"crossref","first-page":"S500","DOI":"10.1245\/s10434-013-2882-0","article-title":"The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma","volume":"20","author":"Abbott","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"0","key":"10.1016\/j.soc.2025.02.001_bib25","article-title":"Borderline resectable pancreatic cancer: a review of recent radiation therapy literature and clinical practice","volume":"6","author":"Nosrati","year":"2023","journal-title":"Dig Med Res"},{"issue":"7","key":"10.1016\/j.soc.2025.02.001_bib26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1001\/jamaoncol.2018.0329","article-title":"Total neoadjuvant therapy with FOLFIRINOX followed by individualized chemoradiotherapy for borderline resectable pancreatic adenocarcinoma: a phase 2 clinical trial","volume":"4","author":"Murphy","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.soc.2025.02.001_bib27","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/cncr.32756","article-title":"Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): an international systematic review and meta-analysis","volume":"126","author":"Tchelebi","year":"2020","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.soc.2025.02.001_bib28","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3109\/0284186X.2015.1004367","article-title":"Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma","volume":"54","author":"Mellon","year":"2015","journal-title":"Acta Oncol Stockh Swed"},{"issue":"9","key":"10.1016\/j.soc.2025.02.001_bib29","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the a021501 phase 2 randomized clinical trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib30","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/bjs\/znac354","article-title":"Surgical resection rates after neoadjuvant therapy for localized pancreatic ductal adenocarcinoma: meta-analysis","volume":"110","author":"Brown","year":"2022","journal-title":"Br J Surg"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib31","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1245\/s10434-010-1282-y","article-title":"Standardization of surgical and pathologic variables is needed in multicenter trials of adjuvant therapy for pancreatic cancer: results from the ACOSOG Z5031 trial","volume":"18","author":"Katz","year":"2011","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00276-008-0353-2","article-title":"Division of the right posterior attachments of the head of the pancreas with a linear stapler during pancreaticoduodenectomy: vascular and oncological considerations based on an anatomical cadaver-based study","volume":"31","author":"Baqu\u00e9","year":"2009","journal-title":"Surg Radiol Anat SRA"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib33","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jamcollsurg.2006.11.002","article-title":"Radical antegrade modular pancreatosplenectomy procedure for adenocarcinoma of the body and tail of the pancreas: ability to obtain negative tangential margins","volume":"204","author":"Strasberg","year":"2007","journal-title":"J Am Coll Surg"},{"issue":"3","key":"10.1016\/j.soc.2025.02.001_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.surg.2014.06.016","article-title":"Definition of a standard lymphadenectomy in surgery for pancreatic ductal adenocarcinoma: a consensus statement by the International Study Group on Pancreatic Surgery (ISGPS)","volume":"156","author":"Tol","year":"2014","journal-title":"Surgery"},{"issue":"3","key":"10.1016\/j.soc.2025.02.001_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/00000658-200209000-00012","article-title":"Pancreaticoduodenectomy with or without distal gastrectomy and extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma, part 2: randomized controlled trial evaluating survival, morbidity, and mortality","volume":"236","author":"Yeo","year":"2002","journal-title":"Ann Surg"},{"issue":"4","key":"10.1016\/j.soc.2025.02.001_bib36","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.surg.2005.06.044","article-title":"A prospective randomized trial comparing standard pancreatoduodenectomy with pancreatoduodenectomy with extended lymphadenectomy in resectable pancreatic head adenocarcinoma","volume":"138","author":"Farnell","year":"2005","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.soc.2025.02.001_bib37","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/archsurg.140.6.584","article-title":"Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer","volume":"140","author":"Pawlik","year":"2005","journal-title":"Arch Surg"},{"issue":"7","key":"10.1016\/j.soc.2025.02.001_bib38","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/s41416-021-01649-7","article-title":"A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study","volume":"126","author":"Su","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.soc.2025.02.001_bib39","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2022.12.014","article-title":"A randomised phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel for locally advanced pancreatic cancer (JCOG1407)","volume":"181","author":"Ozaka","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.soc.2025.02.001_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000024068","article-title":"Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer","volume":"100","author":"Chen","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jhbp.1050","article-title":"Impact of conversion surgery on survival in locally advanced pancreatic cancer patients treated with FOLFIRINOX chemotherapy","volume":"30","author":"Lee","year":"2023","journal-title":"J Hepato-Biliary-Pancreatic Sci"},{"key":"10.1016\/j.soc.2025.02.001_bib42","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1245\/s10434-021-10991-2","article-title":"Neoadjuvant chemotherapy switch in borderline resectable\/locally advanced pancreatic cancer","volume":"29","author":"Alva-Ruiz","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"19","key":"10.1016\/j.soc.2025.02.001_bib43","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1002\/cncr.30780","article-title":"Multiagent induction chemotherapy followed by chemoradiation is associated with improved survival in locally advanced pancreatic cancer","volume":"123","author":"Torgeson","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib44","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1007\/s00066-020-01680-2","article-title":"R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-007\u00b1 trial","volume":"197","author":"Fietkau","year":"2021","journal-title":"Strahlenther Onkol"},{"issue":"7","key":"10.1016\/j.soc.2025.02.001_bib45","doi-asserted-by":"crossref","first-page":"976","DOI":"10.3390\/cancers11070976","article-title":"Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies","volume":"11","author":"van Veldhuisen","year":"2019","journal-title":"Cancers"},{"issue":"10","key":"10.1016\/j.soc.2025.02.001_bib46","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.hpb.2019.02.017","article-title":"Added value of intra-operative ultrasound to determine the resectability of locally advanced pancreatic cancer following FOLFIRINOX chemotherapy (IMAGE): a prospective multicenter study","volume":"21","author":"van Veldhuisen","year":"2019","journal-title":"HPB"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib47","first-page":"127","article-title":"Artery first approach to pancreatic cancer resection: a review of the evidence for benefit","volume":"18","author":"Sanaboyana","year":"2017","journal-title":"J Pancreas"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib48","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1308\/rcsann.2009.91.2.95","article-title":"Portal vein resection during pancreaticoduodenectomy for cancer","volume":"91","author":"Khan","year":"2009","journal-title":"Ann R Coll Surg Engl"},{"issue":"3","key":"10.1016\/j.soc.2025.02.001_bib49","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/bjs.9969","article-title":"Meta-analysis of benefits of portal-superior mesenteric vein resection in pancreatic resection for ductal adenocarcinoma","volume":"103","author":"Giovinazzo","year":"2016","journal-title":"Br J Surg"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib50","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.asjsur.2023.09.039","article-title":"The role of vascular resection and reconstruction in pancreaticoduodenectomy","volume":"47","author":"Li","year":"2024","journal-title":"Asian J Surg"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SLA.0000000000003284","article-title":"Factors predicting response, perioperative outcomes, and survival following total neoadjuvant therapy for borderline\/locally advanced pancreatic cancer","volume":"273","author":"Truty","year":"2021","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.soc.2025.02.001_bib52","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.13131184","article-title":"Pancreatic ductal adenocarcinoma radiology reporting template: consensus statement of the Society of abdominal radiology and the american pancreatic association","volume":"270","author":"Al-Hawary","year":"2014","journal-title":"Radiology"},{"issue":"7","key":"10.1016\/j.soc.2025.02.001_bib53","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1245\/s10434-009-0413-9","article-title":"Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus statement","volume":"16","author":"Abrams","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.02.001_bib54","doi-asserted-by":"crossref","first-page":"e1278","DOI":"10.1097\/SLA.0000000000005395","article-title":"Serum DUPAN-2 could be an alternative biological marker for CA19-9 nonsecretors with pancreatic cancer","volume":"277","author":"Omiya","year":"2023","journal-title":"Ann Surg"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib55","doi-asserted-by":"crossref","first-page":"e698","DOI":"10.1097\/SLA.0000000000004148","volume":"275","author":"Kato","year":"2022","journal-title":"Ann Surg"},{"issue":"11","key":"10.1016\/j.soc.2025.02.001_bib56","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"unstructured":"AHPBA\/SSO\/SSAT consensus conference on resectable and borderline resectable pancreatic cancer: rationale and overview of the conference | Ann Surg Oncol. Available at: https:\/\/link.springer.com\/article\/10.1245\/s10434-009-0409-5. Accessed January 6, 2025.","key":"10.1016\/j.soc.2025.02.001_bib57"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib58","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/XCS.0000000000000212","article-title":"Alterations in somatic driver genes are associated with response to neoadjuvant FOLFIRINOX in patients with localized pancreatic ductal adenocarcinoma","volume":"235","author":"Ecker","year":"2022","journal-title":"J Am Coll Surg"},{"issue":"6","key":"10.1016\/j.soc.2025.02.001_bib59","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1158\/1078-0432.CCR-17-2994","article-title":"Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial","volume":"24","author":"Aung","year":"2018","journal-title":"Clin Cancer"},{"issue":"4","key":"10.1016\/j.soc.2025.02.001_bib60","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1097\/SLA.0000000000002957","article-title":"A phase II clinical trial of molecular profiled neoadjuvant therapy for localized pancreatic ductal adenocarcinoma","volume":"268","author":"Tsai","year":"2018","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.soc.2025.02.001_bib61","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/PPO.0000000000000554","article-title":"PARP inhibitors in pancreatic cancer","volume":"27","author":"Brown","year":"2021","journal-title":"Cancer J Sudbury Mass"},{"key":"10.1016\/j.soc.2025.02.001_bib62","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.pan.2022.06.009","article-title":"Circulating tumor DNA (ctDNA) to evaluate minimal residual disease (MRD), treatment response, and posttreatment prognosis in pancreatic adenocarcinoma","volume":"22","author":"Ueberroth","year":"2022","journal-title":"Pancreatology"},{"issue":"2","key":"10.1016\/j.soc.2025.02.001_bib63","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.pan.2019.01.001","article-title":"FOLFIRINOX for locally advanced pancreatic cancer: results and prognostic factors of subset analysis from a nation-wide multicenter observational study in Japan","volume":"19","author":"Matsumoto","year":"2019","journal-title":"Pancreatology"},{"issue":"23","key":"10.1016\/j.soc.2025.02.001_bib64","doi-asserted-by":"crossref","first-page":"6602","DOI":"10.1158\/1078-0432.CCR-21-1681","article-title":"Organoids derived from neoadjuvant FOLFIRINOX patients recapitulate therapy resistance in pancreatic ductal adenocarcinoma","volume":"27","author":"Farshadi","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.soc.2025.02.001_bib65","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ejso.2021.11.116","article-title":"Long-term nationwide trends in the treatment of and outcomes among pancreatic cancer patients","volume":"48","author":"Aaltonen","year":"2022","journal-title":"Eur J Surg Oncol"},{"issue":"50","key":"10.1016\/j.soc.2025.02.001_bib66","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013592","article-title":"Clinical outcomes of FOLFIRINOX in locally advanced pancreatic cancer","volume":"97","author":"Lee","year":"2018","journal-title":"Medicine (Baltim)"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T16:27:33Z","timestamp":1763051253000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":66,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1055320725000225"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.02.001","relation":{},"ISSN":["1055-3207"],"issn-type":[{"type":"print","value":"1055-3207"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Surgical Resection for Borderline and Locally Advanced Pancreatic Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}